Next Article in Journal
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
Previous Article in Journal
Lactotransferrin Downregulation Drives the Metastatic Progression in Clear Cell Renal Cell Carcinoma
Open AccessFeature PaperArticle

Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis

1
Department of Anatomy and Structural Biology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
2
Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
3
Integrated Imaging Program, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
4
Department of Pathology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
5
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
6
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA
7
Department of Epidemiology and Population Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
8
Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
9
Department of Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(4), 846; https://doi.org/10.3390/cancers12040846
Received: 10 March 2020 / Revised: 25 March 2020 / Accepted: 27 March 2020 / Published: 31 March 2020
Metastasis causes ~90% of breast cancer mortality. However, standard prognostic tests based mostly on proliferation genes do not measure metastatic potential. Tumor MicroEnvironment of Metastasis (TMEM), an immunohistochemical biomarker for doorways on blood vessels that support tumor cell dissemination is prognostic for metastatic outcome in breast cancer patients. Studies quantifying TMEM doorways have involved manual scoring by pathologists utilizing static digital microscopy: a labor-intensive process unsuitable for use in clinical practice. We report here a validation study evaluating a new quantitative digital pathology (QDP) tool (TMEM-DP) for identification and quantification of TMEM doorways that closely mimics pathologists’ workflow and reduces pathologists’ variability to levels suitable for use in a clinical setting. Blinded to outcome, QDP was applied to a nested case-control study consisting of 259 matched case-control pairs. Sixty subjects of these were manually scored by five pathologists, digitally recorded using whole slide imaging (WSI), and then used for algorithm development and optimization. Validation was performed on the remainder of the cohort. TMEM-DP shows excellent reproducibility and concordance and reduces pathologist time from ~60 min to ~5 min per case. Concordance between manual scoring and TMEM-DP was found to be >0.79. These results show that TMEM-DP is capable of accurately identifying and scoring TMEM doorways (also known as MetaSite score) equivalent to pathologists. View Full-Text
Keywords: TMEM; metastasis; prognostic; digital pathology; validation study TMEM; metastasis; prognostic; digital pathology; validation study
Show Figures

Figure 1

MDPI and ACS Style

Entenberg, D.; Oktay, M.H.; D’Alfonso, T.; Ginter, P.S.; Robinson, B.D.; Xue, X.; Rohan, T.E.; Sparano, J.A.; Jones, J.G.; Condeelis, J.S. Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis. Cancers 2020, 12, 846.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop